[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.159.140.188. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 711
Citations 0
News From the Food and Drug Administration
April 5, 2016

New Option for Treating Epilepsy

JAMA. 2016;315(13):1328. doi:10.1001/jama.2016.2689

Brivaracetam has received approval as an add-on to primary therapy for partial-onset seizures in patients with epilepsy who are at least 16 years old (http://1.usa.gov/1Tr6bZT).

The drug, marketed as Briviact, has been studied in more than 2400 adults with partial-onset seizures, according to manufacturer UCB, of Smyrna, Georgia (http://bit.ly/1Ucnrmr). In 1 phase 3 trial, the drug was evaluated in 760 patients aged 16 to 80 years whose current medication didn’t control their seizures.

First Page Preview View Large
First page PDF preview
First page PDF preview
×